Gilead Sciences (GILD) saw various significant events. The biotech company's stock movement was uneven with both dips and increases at different points in time. In terms of partnership news, Gilead entered a
license and option agreement with
Kymera Therapeutics to develop oral molecular glue CDK2 degraders — a new cancer treatment method. This collaboration could result in up to $750 million worth of deals. Meanwhile, GILD has attracted legal investigations for potential investor claims. On the optimistic side,
Jefferies and
Citi Analysts affirmed positive outlooks and a buy rating for Gilead.
RBC Capital also lifted the price target for GILD based on patient survey insights.
Gilead's pipeline momentum and strong financial discipline were highlighted, and the stock was declared a 'safe haven' even after disappointing earnings. There is a negative note on the
HIV treatment trials being placed on clinical hold by the FDA. Yet Gilead also announced positive results from its Phase 3 trial for Trodelvy, a breast cancer treatment.
Gilead Sciences GILD News Analytics from Thu, 09 Jan 2025 08:00:00 GMT to Sat, 28 Jun 2025 08:21:10 GMT -
Rating -1
- Innovation 2
- Information 7
- Rumor -3
